Abstract:Purpose A 50-year-old female with excessive menstruation and severe epistaxis since childhood was studied by using phenotype and genetic diagnosis. She was diagnosed as Glanzmann thrombasthenia (GT), meanwhile, her family members with severe epistaxis were also studied. Mutation sites were detected in them. Bioinformatics software was used to explore the molecular pathogenesis which provide evidence for in vitro and in vivo experiments. Methods Platelet count and morphology, coagulation function and platelet aggregation were detected for phenotype diagnosis. Platelet membrane glycoproteins (GP) αIIb and β3 were measured by flow cytometry (FCM). Exons and their end 15bp introns of 89 genes associated with hemorrhage and thrombosis from proband were amplified by PCR and analyzed by direct DNA sequencing. Mutation site was measured by sanger sequencing in other family members. ClustalX-2.1-win software was used to analyze homology of nucleotide. PROVEAN and SIFT was used to analyze the risk of mutation site. Results The proband, along with her brother and nephew, had normal platelet account and morphology. Coagulation function showed normal while platelet aggregation in response to ADP and AA were reduced. However, they had normal platelet aggregation in response to ristocetin. FCM demonstrated that expression level of CD41 and CD61 were significantly reduced. ITGA2B c.1067T>C heterozygous missense mutation, which led to a Val356→Ala substitution in αIIb protein, existed in the three people. This mutation site was highly conserved among human, mouse, rat and zebrafish. PROVEAN prediction scored -3.48 and SIFT prediction scored 0.001. These results demonstrated ITGA2B p.Val356Ala was pathogenic. Conclusion Glanzmann thrombasthenia is a rare autosomal recessive bleeding disorder results from quantitative or qualitative defect of αIIbβ3 integrin which encoded by ITGA2B and ITGB3. The nature of GT mutations is highly variable and most cases are sporadic. In our study, ITGA2B c.1067T>C (Val356Ala) heterozygous missense mutation caused Glanzmann thrombasthenia and aroused obvious symptoms. And in general, homozygous mutation in ITGA2B were recognized to led to Glanzmann thrombasthenia while ITGA2B heterozygous mutation carriers showed mild symptoms. However, there are also some patients with gain-of-function in ITGA2B showed abnormal platelet function or amount. More experiments should be conducted to identify the function of this heterozygous mutation. Disclosures No relevant conflicts of interest to declare.

When Glanzmann Thrombasthenia Encounters Antithrombin Deficiency: How Do We Balance the Risk and Benefit of Antithrombotic Therapy?

A Rare Glanzmann Thrombasthenia Pedigree of C.1067T>C Heterozygous Mutation in ITGA2B Gene

Pregnancy and childbirth in patients with Glanzmann Thrombasthenia

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

Novel Homozygous Silent Mutation of ITGB3 Gene Caused Glanzmann Thrombasthenia

Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions

A Novel Pro126his Beta Propeller Mutation in Integrin Alpha Iib Causes Glanzmann Thrombasthenia by Impairing Progression of Pro-Alpha Iib Beta 3 from Endoplasmic Reticulum to Golgi

New Compound Heterozygous Mutations of GPIIb in Patient with Glanzmann Thrombasthenia.

SINE-VNTR-Alu Retrotransposon Insertion As a Novel Mutational Event Underlying Glanzmann Thrombasthenia.

Clinical and Molecular Insights into Glanzmann's Thrombasthenia in China

Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study

Pathogenesis and prenatal diagnosis of hereditary Glanzmann thrombasthenia

[Molecular Analysis of Gene Mutations in Eight Patients with Glanzmann's Thrombasthenia].

Study on the Clinical Phenotype and Mechanism in Five Chinese Pedigrees with Glanzmann Thrombasthenia

[Analysis of Clinical Features and Genotype in Three Chinese Pedigrees with Glanzmann Thrombasthenia].

Management of Abdominal Aortic Aneurysm Surgery in Glanzmann's Thrombasthenia Patients with Anti-GPIIb-IIIa Antibodies: A Case Report

Glanzmann’s thrombasthenia: identification of 19 new mutations in 30 patients

Glanzmann Thrombasthenia Caused by a Novel Pro126His Mutation in the Integrin Α_(iib)

Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab

Treatment of inherited platelet disorders

Phenotype and genotype diagnosis in five Chinese pedigrees with Glanzmann thrombasthenia